TANG KEVIN 4

What Happened
Kevin Tang, a reported 10% owner of Boundless Bio (BOLD), purchased a total of 286,333 common shares in multiple open‑market transactions between June 25 and June 29, 2026. The filing reports weighted‑average prices for the lots and shows aggregate cash outlay of approximately $714,768. These transactions are purchases (insider buying), which investors often view as a positive signal, though the filing does not state Mr. Tang’s motivation.

Key Details

• Transactions (date — shares — weighted‑avg price — reported value):
  • 2026-06-25 — 145,880 @ $2.48 — $361,782
  • 2026-06-25 — 510 @ $2.56 — $1,306
  • 2026-06-26 — 75,047 @ $2.55 — $191,370
  • 2026-06-26 — 134 @ $2.54 — $340
  • 2026-06-29 — 63,985 @ $2.47 — $158,043
  • 2026-06-29 — 777 @ $2.48 — $1,927
• Total purchased: 286,333 shares for about $714,768.
• Prices reported are weighted averages; the filing notes the actual trades occurred across price ranges roughly $2.40–$2.60 (see footnotes).
• Ownership after transaction: the excerpt does not list Mr. Tang’s total post‑transaction holdings. Footnote F2 shows related entities (TCP, TCPI, TCP III, TCP IV) and states Mr. Tang has a pecuniary interest in those holdings.
• Transaction code: P = Purchase (open market/private purchase).
• Filing timeliness: Report lists transactions through 6/29/2026 and was filed 6/29/2026 — timely under Form 4 reporting rules.

Context

• Mr. Tang is identified as a 10% beneficial owner with interests through multiple Tang Capital entities (see footnote F2). These purchases were made in multiple trades; the reporting persons offer to provide the per‑trade breakdown on request.
• Insider purchases are factual data points; they do not prove future performance or disclose the insider’s intent.